CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a new, state-of-the-art facility in Saint-Beauzire, France.
 
The 9,500m² facility is dedicated to the custom development and production of sterile injectable drug products. Built on newly acquired land near CARBOGEN AMCIS’ site in Riom, the new facility increases product development and manufacturing capacity for liquid and freeze-dried products for pre-clinical and clinical trials as well as small-scale commercial use.
 
The facility forms two new fully-automated production lines for liquid and freeze-dried drug products, including highly potent compounds and advanced therapies such as antibody drug conjugates enabling increased customer access. The lines offer a flexible and versatile set up, and comes at a time when securing fill finish capacity in Europe can be a challenge for many pharmaceutical companies.
 
Pascal Villemagne, CEO of CARBOGEN AMCIS Group, said, “Over the last six years, CARBOGEN AMCIS has continued to expand our facilities and grow our capacity, enabling us to support more customers and increase access to new and diverse technologies and services.
 
“Our new site will enable us to fully synergize our world-class chemistry skills and continue to bring our customers’ science to life, helping us play our part in the roll-out of new and better treatments, which help improve patients’ quality of life or treat otherwise terminal illness.”
 
The site will house approximately 100 highly-skilled employees and create 50 new jobs throughout 2023.